The risk of hypoglycemia associated with SGLT2 inhibitors is low because of the compensation provided by SGLT1 in the late proximal tubule, which eliminates glucose excretion when filtered glucose falls below the transport capacity of SGLT1. This evidence concerns the gene SLC5A1 and Hypoglycemia.